{"name":"Humanigen","slug":"humanigen","ticker":"HGEN","exchange":"NASDAQ","domain":"humanigen.com","description":"Humanigen is a biopharmaceutical company focused on developing treatments for various diseases, particularly in the areas of immuno-oncology and supportive care. The company's top drugs include lenzilumab, which is being developed for the treatment of COVID-19 and other conditions. Humanigen has a strong pipeline of products in various stages of development, with several in phase 2 and phase 3 clinical trials. The company is well-positioned to capitalize on the growing demand for innovative treatments in these areas.","hq":"Brisbane, CA","founded":0,"employees":"","ceo":"Cameron Durrant","sector":"Immuno-Oncology / Supportive Care","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$120M","metrics":{"revenue":2514000,"revenueGrowth":-30.1,"grossMargin":0,"rdSpend":55210000,"netIncome":-70730000,"cash":11195000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"lenzilumab patent cliff ($0.0B at risk)","drug":"lenzilumab","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2022-06-28","type":"regulatory","headline":"Humanigen Announces FDA Clearance of IND for Lenzilumab in COVID-19","summary":"Humanigen announced that the FDA has cleared the Investigational New Drug (IND) application for lenzilumab in COVID-19.","drugName":"lenzilumab","sentiment":"positive"},{"date":"2022-03-21","type":"earnings","headline":"Humanigen Reports Fourth Quarter and Full Year 2021 Financial Results","summary":"Humanigen reported its financial results for the fourth quarter and full year 2021, highlighting progress in its pipeline and financial performance.","drugName":"","sentiment":"neutral"},{"date":"2021-12-01","type":"deal","headline":"Humanigen Announces Collaboration with Merck to Develop Lenzilumab in Combination with Keytruda","summary":"Humanigen announced a collaboration with Merck to develop lenzilumab in combination with Keytruda for the treatment of various cancers.","drugName":"lenzilumab","sentiment":"positive"}],"realNews":[{"date":"2024-01-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQRlRueWNuWXliMUpBTXAyekpnSkgwLWozR1NkYWthOUtHR1Z1VlJRTklmTmVBR1BFNGxPOXRnZGtURHpiZm1yRksxQXVPdUd0Q3dDLUVOSG02LXdyRkZreWhIZFlDai1IUi1ndllCejNXa0VUY3JycGtRaWRWRkZLb0htOTkxbVo1WEhDM1Y0cDZaWjM5Qjc2d0lrZFBqdw?oc=5","date":"2024-01-05","type":"pipeline","source":"thestreet.com","summary":"Controversial health-care company files for Chapter 11 bankruptcy - thestreet.com","headline":"Controversial health-care company files for Chapter 11 bankruptcy","sentiment":"neutral"},{"date":"2023-09-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOSjlWdzBxOFdGSFNDR2diNl9vV2V0anl3MG1wb2ozR2U1RzRDYnZtMFlxSk9HYVpKTGtXTWdPTGpXQW1xU1M2UHN5NExwNkxvY015UFd5NENvU0o0bGhpdVJaOVRtY2Z0TmpieGlOeV96U0lmS0pXOXFIQXZRS0FMY2NFQlNWdUpBcHRMSzY2MGY2cElIak9yYTBmR2dtWlc4UVdaN0pJeENuWXNaY0wyUjN2YXNjUWFGSzI4a003RWlUQ0E2VWJzRG0wSEd1UVJ4dDAxbE1qLXI5U2NLbThYTw?oc=5","date":"2023-07-28","type":"pipeline","source":"proactiveinvestors.com","summary":"Humanigen stock removed from S&P Total Market Index as firm faces bankruptcy - proactiveinvestors.com","headline":"Humanigen stock removed from S&P Total Market Index as firm faces bankruptcy","sentiment":"neutral"},{"date":"2023-07-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-05-15","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2023-04-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-04-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2023-03-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2022-12-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2022-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2022-11-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"}],"patents":[{"drugName":"lenzilumab","drugSlug":"lenzilumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Bristol-Myers Squibb","Merck & Co.","Gilead Sciences"],"therapeuticFocus":["Immuno-Oncology","Supportive Care"],"financials":{"source":"sec_edgar+yahoo","revenue":2514000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":2514000,"period":"2022-12-31"},{"value":3595000,"period":"2021-12-31"},{"value":3595000,"period":"2021-12-31"},{"value":312000,"period":"2020-12-31"},{"value":312000,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":55210000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-70730000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":11195000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}